Clinical trial
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
NCT02812420 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 7, 2017
- Completion date
- December 31, 2027
- Enrollment
- 54 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hydronephrosis, infiltrating bladder urothelial carcinoma sarcomatoid variant, infiltrating bladder urothelial carcinoma, micropapillary variant, infiltrating bladder urothelial carcinoma, plasmacytoid variant, infiltrating renal pelvis urothelial carcinoma, sarcomatoid variant, renal pelvis urothelial carcinoma, stage ii bladder urothelial carcinoma ajcc v6 and v7, stage ii renal pelvis cancer ajcc v7, stage ii ureter cancer ajcc v7, stage ii urethral cancer ajcc v7, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iii renal pelvis cancer ajcc v7, stage iii ureter cancer ajcc v7, stage iii urethral cancer ajcc v7, stage iv renal pelvis cancer ajcc v7, stage iv ureter cancer ajcc v7, stage iv urethral cancer ajcc v7, ureter urothelial carcinoma, urethral urothelial carcinoma